Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

@article{Cocquyt2001ComparisonOL,
  title={Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.},
  author={Veronique F J Cocquyt and Simon Van Belle and Rick R Reinhardt and Marc Decramer and Mary O'brien and Jan H. M. Schellens and Marleen Borms and L M J Verbeke and Filip Van Aelst and Marina De Smet and Alexandra D. Carides and Krista Eldridge and Barry J. Gertz},
  journal={European journal of cancer},
  year={2001},
  volume={37 7},
  pages={835-42}
}
Substance P is localised in brainstem regions associated with emesis. Based on studies in the ferret, it was postulated that a neurokinin-1 (NK1) receptor antagonist would have antiemetic activity as monotherapy in humans receiving chemotherapy. L-758,298 is a water-soluble, intravenous (i.v.) prodrug for L-754,030, a potent and selective NK1 receptor antagonist. This double-blind, randomised, active-agent (ondansetron)-controlled study enrolled 53 cisplatin-naïve patients and evaluated the… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…